Closing the Loop

Revital Nimri, Pearl Audon, Jordan E. Pinsker, Eyal Dassau

Research output: Contribution to journalArticlepeer-review


This year's articles showed the true potential of AP in the outpatient setting. The next step is to take the systems studied and subject them to rigorous randomized controlled outpatient home use trials. As shown in a recent systematic review and meta-analysis, there remain a number of unanswered questions, particularly in studies with remote monitoring that may lead to improved reporting of results (12). Future long-term studies will prove the efficacy of single- and dual-hormone systems, and it is only through rigorous, structured controlled trials in the anticipated real-world home use setting (i.e., without remote monitoring) that investigators will be able to improve AP devices to optimize outcomes. The greatest breakthrough and important milestone in the pathway of implementation of closed-loop systems to regular diabetes treatment was recently made by the FDA approval of the first Medtronic hybrid closed-loop system. Ultimately, patients with diabetes will benefit greatly from the number of systems under development by commercial entities.

Original languageEnglish
Pages (from-to)S41-S54
JournalDiabetes Technology and Therapeutics
Issue numberS1
StatePublished - Feb 2018
Externally publishedYes


Dive into the research topics of 'Closing the Loop'. Together they form a unique fingerprint.

Cite this